Kyverna Therapeutics released interim Phase II results showing strong efficacy for KYV‑101, an autologous CD19 CAR‑T with CD28 costimulation, in generalized myasthenia gravis (gMG). The company said it will move to Phase III later this year after high response rates and clinically meaningful improvements on MG‑ADL and QMG scales. In a small cohort, Kyverna reported that all evaluable patients achieved meaningful functional responses and several reached minimal symptom expression; the safety profile included cytokine release syndrome, mostly Grade 1–2. The company contrasted its responses with historical data from competing approaches and noted durable trends in motor scores. Kyverna plans to start pivotal work by year‑end; observers cautioned cross‑trial comparisons but acknowledged the data support registrational intent. Payers and specialists will watch confirmatory Phase III results and long‑term safety to gauge the therapy’s competitive positioning versus other emerging immune‑modulatory and cell‑therapy approaches.